We next measured the plasma levels of two more biomarkers linked to inflammatory states at week 0 (baseline) and week 24: fractalkine (CX3CL1), a marker of endothelial dysfunction, and IL-18, a marker of inflammasome activation (Supplementary Table 2), and found no differences of these markers between placebo and LDMTX arms. Here, CX3CL1 is linked to endothelial dysfunction.